Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors
2008

HIV-1 Integrase Variants and Antiretroviral Resistance

Sample size: 1800 publication Evidence: high

Author Information

Author(s): Rhee Soo-Yon, Liu Tommy F, Kiuchi Mark, Zioni Rafael, Gifford Robert J, Holmes Susan P, Shafer Robert W

Primary Institution: Stanford University

Hypothesis

The study aims to characterize the distribution of integrase variants among HIV-1 group M isolates and their implications for antiretroviral therapy.

Conclusion

The study found that integrase displayed higher levels of amino acid conservation compared to other viral enzymes, with most known resistance mutations being nonpolymorphic.

Supporting Evidence

  • Polymorphism rates equal or above 0.5% were found for 34% of the central core domain positions.
  • Integrase displayed significantly decreased inter- and intra-subtype diversity compared to protease or RT.
  • Most primary INI-resistance mutations were nonpolymorphic.

Takeaway

Researchers looked at the differences in a part of the HIV virus called integrase from many people to see how it might affect treatment options.

Methodology

The study analyzed over 1,800 published group M HIV-1 integrase sequences from more than 1,500 individuals who had not been treated with integrase inhibitors.

Limitations

The study excluded sequences of poor quality and those with insufficient annotation.

Participant Demographics

The study included more than 1,500 integrase inhibitor-naïve individuals.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/1742-4690-5-74

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication